Research Article

Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study

Table 2

Multivariate analyses of prognostic factors for progression-free survival in all sorafenib-treated patients ().

CategoryUnivariate analysis of PFSMultivariate analysis of PFS
Hazard ratio valueConfidence intervalHazard ratio valueConfidence interval

Gender, female0.760.2280.48–1.19
Age ≥65 years1.100.6200.76–1.59
KPS <80%1.150.6540.63–2.09
LDH >1.5x ULN1.320.5110.57–3.04
Hemoglobin <LLN1.620.0121.11–2.370.860.7240.36–2.02
cCa >10 mg/dL0.880.7690.39–2.02
Time from diagnosis to treatment <1 year1.99<0.0011.37–2.901.320.5310.56–3.12
Leukocytosis1.820.1140.87–3.80
Thrombocytosis3.240.0021.54–6.820.700.6770.13–3.75
Hypoalbuminemia1.230.5410.64–2.36
Prior nephrectomy0.830.7510.26–2.63
Prior metastasectomy0.930.7230.61–1.41
Brain metastasis0.970.8810.64–1.47
Bone metastasis1.380.1170.92–2.07
Liver metastasis2.010.0251.09–3.711.660.3770.54–5.08
Lung metastasis0.770.1920.52–1.14
Lymph node metastasis1.240.3400.80–1.93
Pancreas1.170.6730.57–2.40
Contralateral kidney0.220.0360.05–0.910.290.2860.03–2.80
Metastatic sites
 11.00
 2-31.040.8450.71–1.52
 ≥41.290.5320.58–2.85
T stage
 T1-21.001.00
 T3-41.550.0281.05–1.522.560.0341.08–6.09
 N12.260.0011.38–2.851.310.7140.31–5.54
 M11.980.0331.06–2.300.840.7210.31–2.22
Fuhrman grade
 1-21.00
 3-40.960.8570.63–3.68
Tumor-related factor
Primary tumor size
 <4 cm1.001.00
 4–7 cm0.920.8110.45–1.870.540.2810.18–1.66
 >7 cm0.780.4470.40–1.490.340.0450.12–0.98
Collecting system invasion1.670.0451.01–2.740.730.5820.24–2.23
Capsule invasion1.010.9810.62–1.64
Lymphovascular invasion2.130.0041.27–3.572.010.3240.5–8.09
Tumor necrosis2.130.0031.30–3.472.360.0550.98–5.65
Immunotherapy1.00
Other therapy0.960.8580.62–1.5

KPS, Karnofsky performance status; LDH, lactate dehydrogenase; ULN, upper limit normal; LLN, lower limit normal; cCa, corrected calcium.